The insurer points to early research on peptides for plaque control, gum health and rebuilding enamel. It's a brief explainer, not a new study.
Recap by typeshit. Post by @deltadentalnjct on Instagram.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
The cookie chain built on oversized treats faces added pressure from Ozempic and Wegovy, with surveys pointing to changing snack habits among users.
EMY reports the FDA has added a fresh warning covering Wegovy and similar weight loss drugs. Tap through for what the label change says.
Loading…